Transcode Therapeutics Files 8-K
Ticker: RNAZ · Form: 8-K · Filed: Oct 14, 2025 · CIK: 1829635
| Field | Detail |
|---|---|
| Company | Transcode Therapeutics, INC. (RNAZ) |
| Form Type | 8-K |
| Filed Date | Oct 14, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing, pharmaceuticals
TL;DR
Transcode Therapeutics filed an 8-K on Oct 13, 2025. Details pending.
AI Summary
Transcode Therapeutics, Inc. filed an 8-K on October 14, 2025, reporting an event that occurred on October 13, 2025. The filing is primarily for "Other Events" and "Financial Statements and Exhibits." The company, incorporated in Delaware with its principal executive offices in Boston, MA, operates in the Pharmaceutical Preparations sector.
Why It Matters
This 8-K filing indicates that Transcode Therapeutics has made a regulatory submission, which could relate to significant corporate events or financial disclosures.
Risk Assessment
Risk Level: low — This filing is a standard 8-K for 'Other Events' and 'Financial Statements and Exhibits' without immediate disclosed material changes.
Key Numbers
- 001-40363 — SEC File Number (Identifies the company's filing with the SEC.)
- 81-1065054 — EIN (Employer Identification Number for tax purposes.)
Key Players & Entities
- Transcode Therapeutics, Inc. (company) — Registrant
- October 13, 2025 (date) — Earliest event reported
- October 14, 2025 (date) — Date of report
- Boston, Massachusetts (location) — Principal executive offices
- 2834 (industry_code) — Standard Industrial Classification
FAQ
What specific 'Other Events' are being reported by Transcode Therapeutics?
The provided text does not detail the specific 'Other Events' beyond listing it as an item information category.
What is the nature of the 'Financial Statements and Exhibits' being filed?
The filing indicates that financial statements and exhibits are part of this 8-K, but their specific content is not detailed in the provided excerpt.
What is the significance of the filing date being October 14, 2025, and the earliest event date being October 13, 2025?
This indicates that the report is current, covering events that occurred on the day prior to the filing.
What is Transcode Therapeutics, Inc.'s primary business sector?
Transcode Therapeutics, Inc. is in the 'PHARMACEUTICAL PREPARATIONS' sector, with SIC code 2834.
Where are Transcode Therapeutics, Inc.'s principal executive offices located?
The principal executive offices are located at 6 Liberty Square, #2382, Boston, Massachusetts 02109.
Filing Stats: 830 words · 3 min read · ~3 pages · Grade level 14 · Accepted 2025-10-14 08:11:31
Key Financial Figures
- $0.0001 — registered Common Stock, par value $0.0001 per share RNAZ The Nasdaq Capital
Filing Documents
- tm2528668d1_8k.htm (8-K) — 27KB
- tm2528668d1_ex99-1.htm (EX-99.1) — 15KB
- tm2528668d1_ex99-2.htm (EX-99.2) — 9KB
- tm2528668d1_ex99-1img001.jpg (GRAPHIC) — 17KB
- tm2528668d1_ex99-1img002.jpg (GRAPHIC) — 6KB
- tm2528668d1_ex99-2img001.jpg (GRAPHIC) — 2890KB
- 0001104659-25-099029.txt ( ) — 4240KB
- rnaz-20251013.xsd (EX-101.SCH) — 3KB
- rnaz-20251013_lab.xml (EX-101.LAB) — 33KB
- rnaz-20251013_pre.xml (EX-101.PRE) — 22KB
- tm2528668d1_8k_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On October 14, 2025, TransCode Therapeutics, Inc. ("TransCode") issued a press release announcing completion of its Phase 1a clinical trial with TTX-MC138. A copy of this press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. A copy of the related poster is attached hereto as Exhibit 99.2 and incorporated herein by reference. Note Regarding Forward-Looking Statements This Current Report on Form 8-K contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements concerning the timing, conduct and results of TransCode's Phase 1a clinical trial, TransCode's Phase 2a clinical trial, and TransCode's Phase 2 clinical trial, statements about microRNAs and their involvement in cancer, and statements concerning the therapeutic potential of TransCode's TTX-MC138 and other therapeutic candidates. Any forward-looking statements in this Current Report on Form 8-K are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risks associated with drug discovery and development; the risk that the results of clinical trials will not be consistent with TransCode's preclinical studies or expectations or with results from previous clinical trials; risks associated with the conduct of clinical trials; risks associated with TransCode's financial condition and its need to obtain additional funding to support its business activities, including TransCode's ability to continue as a going concern; risks associated with the timing and outcome of TransCode's planned regulatory submissions; risks associated with obtaining, maintaining and protecting intellectual property; risks associate
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated October 14, 2025 99.2 Poster, dated October 13, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TransCode Therapeutics, Inc. Date: October 14, 2025 By: /s/ Philippe Calais Philippe Calais Chief Executive Officer